|Bid||5.19 x 4000|
|Ask||0.00 x 27000|
|Day's Range||9.27 - 9.81|
|52 Week Range||7.11 - 14.62|
|Beta (3Y Monthly)||1.57|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Yet another company wants to secure office space in Lake Nona, the fast-growing southeast Orlando suburb. Miami-based Pipeline Orlando LLC is in talks with Lake Nona developer Tavistock Development Co.
A land deal between Lake Nona's developer and a New Jersey biotech firm sets the stage for the latter company to bring new high-wage jobs and commercial development to southeast Orlando. Cranbury, New Jersey-based tech and biopharmaceutical company Amicus Therapeutics Inc. (Nasdaq: FOLD) bought 5.2 acres for $3.1 million, or roughly $596,153 an acre, in Lake Nona's 650-acre Medical City, according to Orange County records. Orlando-based Tavistock Development Co.'s Lake Nona Land Co. LLC was the seller.
Amicus Therapeutics (FOLD) delivered earnings and revenue surprises of 25.00% and 1.47%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
PCTEL's (PCTI) third-quarter performance is likely have benefited from the demand for 5G scanning receivers and Industrial IoT antenna project wins.
Zynerba Pharmaceuticals' (ZYNE) operating expenses are expected to have increased in the third quarter driven by clinical studies on its lead pipeline candidate, Zygel.
Amicus Therapeutics (FOLD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Hedge funds are known to underperform the bull markets but that's not because they are bad at investing. Truth be told, most hedge fund managers and other smaller players within this industry are very smart and skilled investors. Of course, they may also make wrong bets in some instances, but no one knows what the […]
Amicus Therapeutics (FOLD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
John Crowley became the CEO of Amicus Therapeutics, Inc. (NASDAQ:FOLD) in 2011. This report will, first, examine the...
Amicus Therapeutics (FOLD) delivered earnings and revenue surprises of 0.00% and 7.32%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Amicus Therapeutics (FOLD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.